@article{0b52eb16fe924c8fbb7d3d611e42277c,
title = "ULK1 as a novel therapeutic target in neurodegeneration",
author = "Bj{\"o}rn Vahsen and Paul Lingor",
note = "Funding Information: Finally ? we confirmed some of the key findings of disease.for a therapeutic modulation of ULK1 in human U?? 堀᠀䔃爁甁ḁᨁ崁?ted U?? inhibition using the small ? al., 2020). Indeed, treatment of retinal ganglionmolecule ULK1inhibitorSBI-0206965(Vahsenet BFV?was?supported?by?a?scholarship?from?the? DepartmentofNeurology ,UniversityMedic al? cells with SBI-0206965 attenuated AAD for up to Center?G{\"o}ttingen.?PL?received?funding?from?the? 6 hours after optic nerve crush lesion in a dose-Cluster?of?Excellence?and?DFG?Research?Center? dependent manner. Corresponding to our results Nanoscale?Microscopy?and?Molecular?Physiology?",
year = "2021",
month = jun,
doi = "10.4103/1673-5374.300442",
language = "English",
volume = "16",
pages = "1212--1213",
journal = "Neural Regeneration Research",
issn = "1673-5374",
publisher = "Wolters Kluwer Medknow Publications",
number = "6",
}